Chunyao Zhou1, Yongheng Wang2,3, Xing Liu1,2, Yuchao Liang1, Ziwen Fan1, Tao Jiang1,2,4, Yinyan Wang5,6, Lei Wang7,8. 1. Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 6 Tiantanxili, Beijing, China. 2. Beijing Neurosurgical Institute, Capital Medical University, Beijing, China. 3. Department of Neurosurgery, Qinhuangdao First Hospital, Hebei, China. 4. Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing, China. 5. Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 6 Tiantanxili, Beijing, China. tiantanyinyan@126.com. 6. Beijing Neurosurgical Institute, Capital Medical University, Beijing, China. tiantanyinyan@126.com. 7. Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 6 Tiantanxili, Beijing, China. wanglei_tiantan@163.com. 8. Beijing Neurosurgical Institute, Capital Medical University, Beijing, China. wanglei_tiantan@163.com.
Abstract
BACKGROUND: The newly proposed putamen classification system shows good prognostic value in patients with insular LGGs, yet no study towards the molecular profiles of putamen involved LGGs has been proposed. METHODS: Clinical information and imaging data of patients diagnosed with insular low-grade gliomas were collected retrospectively. Genetic information of the 34 tumors was assessed using RNA-sequencing. Gene set enrichment analysis was further performed to identify the genes showing differential expression between putamen-involved tumors and putamen non-involved tumors. The level of Ki-67 expression was also evaluated. RESULTS: There were 843 genes identified to be differentially expressed between putamen-involved and non-involved gliomas. Specifically, Gene set enrichment analysis discovered 13 Kyoto Encyclopedia of Genes and Genomes pathways and 37 Gene Ontology Biological Process term were upregulated in putamen-involved low-grade glioma cells. The enriched GO sets with the highest gene counts included cell cycle (42 genes), mitotic cell cycle (24 genes), and cell division (19 genes). Furthermore, high expression of Ki-67 was associated with putamen involvement in insular gliomas. CONCLUSIONS: There is clear genetic variation between putamen-involved and non-involved insular low-grade gliomas. The differential expression of genes related to the processes of cell proliferation, cell migration, or DNA repair may lead to putamen involvement. The findings suggest that among the two subtypes, putamen-involved insular low-grade gliomas have higher malignancy, and the clinical treatment towards the putamen-involved insular low-grade gliomas should be more active.
BACKGROUND: The newly proposed putamen classification system shows good prognostic value in patients with insular LGGs, yet no study towards the molecular profiles of putamen involved LGGs has been proposed. METHODS: Clinical information and imaging data of patients diagnosed with insular low-grade gliomas were collected retrospectively. Genetic information of the 34 tumors was assessed using RNA-sequencing. Gene set enrichment analysis was further performed to identify the genes showing differential expression between putamen-involved tumors and putamen non-involved tumors. The level of Ki-67 expression was also evaluated. RESULTS: There were 843 genes identified to be differentially expressed between putamen-involved and non-involved gliomas. Specifically, Gene set enrichment analysis discovered 13 Kyoto Encyclopedia of Genes and Genomes pathways and 37 Gene Ontology Biological Process term were upregulated in putamen-involved low-grade glioma cells. The enriched GO sets with the highest gene counts included cell cycle (42 genes), mitotic cell cycle (24 genes), and cell division (19 genes). Furthermore, high expression of Ki-67 was associated with putamen involvement in insular gliomas. CONCLUSIONS: There is clear genetic variation between putamen-involved and non-involved insular low-grade gliomas. The differential expression of genes related to the processes of cell proliferation, cell migration, or DNA repair may lead to putamen involvement. The findings suggest that among the two subtypes, putamen-involved insular low-grade gliomas have higher malignancy, and the clinical treatment towards the putamen-involved insular low-grade gliomas should be more active.
Authors: Anastasia Murat; Eugenia Migliavacca; Thierry Gorlia; Wanyu L Lambiv; Tal Shay; Marie-France Hamou; Nicolas de Tribolet; Luca Regli; Wolfgang Wick; Mathilde C M Kouwenhoven; Johannes A Hainfellner; Frank L Heppner; Pierre-Yves Dietrich; Yitzhak Zimmer; J Gregory Cairncross; Robert-Charles Janzer; Eytan Domany; Mauro Delorenzi; Roger Stupp; Monika E Hegi Journal: J Clin Oncol Date: 2008-06-20 Impact factor: 44.544
Authors: Andrea Scrima; Renata Konícková; Bryan K Czyzewski; Yusuke Kawasaki; Philip D Jeffrey; Regina Groisman; Yoshihiro Nakatani; Shigenori Iwai; Nikola P Pavletich; Nicolas H Thomä Journal: Cell Date: 2008-12-26 Impact factor: 41.582
Authors: Emma van Kessel; Tom J Snijders; Anniek E Baumfalk; Carla Ruis; Kirsten M van Baarsen; Marike L Broekman; Martine J E van Zandvoort; Pierre A Robe Journal: J Neurooncol Date: 2019-12-04 Impact factor: 4.130